Biohaven (BHVN) Cash from Operations Growth (1y) (2022 - 2026)

Biohaven (BHVN) Cash from Operations Growth (1y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 4.87%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -28.96%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 75.58%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -119.28%
7 Royalty Pharma 33.72 Bn 35.84 Bn - 100.14%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 151.70%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 56.79%
10 Biohaven 2.21 Bn 1.94 Bn - 49.33%

Historic Data

Download Data
DateValue
Jun 30, 2026 49.33%
Mar 31, 2026 9.21%
Dec 31, 2025 23.47%
Sep 30, 2025 -3.14%
Jun 30, 2025 -0.08%
Mar 31, 2025 -60.88%
Dec 31, 2024 -48.63%
Sep 30, 2024 -49.00%
Jun 30, 2024 -277.98%
Mar 31, 2024 -32.20%
Dec 31, 2023 -52.35%
Sep 30, 2023 0.78%
Jun 30, 2023 34.61%
Mar 31, 2023 -31.96%
Dec 31, 2022 -128.12%